About Axis Research

Education first.
Always.

We started Axis Research because we noticed a gap — complex science locked behind jargon, and products sold without proof. We're here to change that.

Making research accessible

Axis Research Lab exists to bridge the gap between complex peptide science and the researchers who need to understand it. Every compound profile, every COA, every educational resource is designed to make informed research decisions easier.

Education First

We lead with knowledge, not sales pitches. Every compound in our library includes detailed research summaries, mechanism breakdowns, and published study references.

Compliance Focused

All content and products are framed within Research Use Only (RUO) compliance. No medical claims, no therapeutic language, no ambiguity about intended use.

Batch Verified

Every product linked from our library comes with batch-specific Certificates of Analysis. No generic testing, no outdated results — real data tied to real batches.

Two platforms, one standard

Axis Research Lab is the education and verification hub — compound profiles, batch-tested research, COA verification, and AI-assisted research guidance. Every material is traceable to its source.

Axis Research Lab

Education, compound profiles, COA verification, and AI-assisted research guidance. Learn and verify before you buy.

Batch-Tested Research

Every compound in our library is sourced from verified suppliers with full batch traceability. Each product links back to its Certificate of Analysis.

For Research Use Only

All compounds referenced on this website are designated for Research Use Only (RUO). They are not intended for human consumption, therapeutic use, or diagnostic purposes. Nothing on this site constitutes medical advice, and no therapeutic claims are made or implied.

Axis Research Lab provides educational content and verification tools. Product availability is subject to applicable research compliance regulations. By using this site, you acknowledge that all materials are for legitimate research purposes only.

FDA Pharmacy Compounding Advisory Committee — July 2026

The FDA's Pharmacy Compounding Advisory Committee (PCAC) convenes July 23–24, 2026 to evaluate peptide research compounds for inclusion on the 503A Bulk Drug Substances List. This hearing will review regulatory status and research access for compounds in our library.

We remain committed to education-first research in a transparent regulatory environment. For a detailed breakdown of the PCAC agenda, affected compounds, and timeline, see our comprehensive regulatory update.

Read the Full PCAC Breakdown →

Ready to start your research?

Browse our compound library or learn about COA verification.

Research Library → COA Verification →

📡 Research updates from Axis Research Lab — regulatory updates, new compound profiles, COA alerts.

⚠️ FDA PCAC: -- days left

No spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →